Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver
Randomized Placebo-Control Pilot Study Evaluating the Efficacy and Safety of Rosiglitazone Combined With Pegylated Interferon Plus Ribavirin Versus Pegylated Interferon Plus Ribavirin Alone in Genotype 1 Hepatitis C With Steatosis
研究概览
详细说明
Eligible thirty subjects will be randomized in a double blinded fashion to either Rosiglitazone 4mg pills twice a day versus placebo for six weeks. Then after this six week period, both groups will be treated for 48 weeks of standard therapy for hepatitis C consisting of Pegasys 180mcq weekly injections with Ribavirin 1,000mg-1,200mg daily depending if the subject weights less than 75 kg will then receive the lower dosage. In addition, the subjects will be continued on Rosiglitazone or placebo for the 48 weeks.
The subjects will be monitored for side-effects by history taking and blood testing at predetermined time periods during the study. If the viral load has not dropped more than two log at week 12 of standard therapy for hepatitis C then therapy will be stopped and the subject is considered a treatment failure. Similarly, if there was a greater than two log drop in the viral load at week 12 but there is still virus present in the blood at week 24 then therapy is stopped and the subject is considered treatment failure. If the virus is undetectable in the blood at week 12 and 24 then therapy is continued for the full 48 weeks. If the virus is detectable at week 48 then the subject is considered a treatment failure.
After this 48 week treatment period and the virus is still undetectable, there is a follow-up period consisting of 24 weeks off therapy. At the end of the 24 weeks, blood will be tested for the virus and if the virus is not present then the subject has a sustained viral response and is a treatment success.
During therapy if the subject becomes significantly anemic Procrit 40,000Units weekly injections will be started. Similarly, if the white blood cell count drops below a certain level then weekly Neupogen 300mcq injections will be started. In addition, if there is mild depressive symptoms treatment will be started but if there is major depressive symptoms, then therapy will be stopped and a referral to a psychiatrist will be made.
研究类型
注册 (预期的)
阶段
- 第四阶段
联系人和位置
学习地点
-
-
New York
-
New York、New York、美国、10003
- Beth Israel Medical Center - Philipps Ambulatory Care Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Men and women at least 21 years of age.
- Positive serum hepatitis C RNA for at least 6 months.
- Naive to any therapy for hepatitis C infection.
- Significant steatosis or fat on the liver biopsy.
- Genotype 1 patients.
Exclusion Criteria:
- Subjects with decompensated liver disease.
- Hemoglobin <12g/dl.
- WBC<2,000mm3.
- ANC<1,000mm3.
- Platelet count<50,000/mm3.
- Creatinine>1.5mg/dl.
- Albumin<2.5g/dl.
- Bilirubin>4mg/dl.
- HIV or hepatitis B co-infection.
- History of other liver disease besides fatty liver disease.
- History of unstable cardiac or cerebrovascular disease.
- History of significant psychiatric disorders.
- Alcohol or drug abuse within last year.
- Pregnant or lactating women or men whose sexual partner is pregnant or lactating.
- Taking of insulin or oral hypoglycemic agents within six months of the study.
- Uncontrolled thyroid disorder.
- History of malignancy within the past 5 years unless cured by surgery.
- History of autoimmune disorder or organ transplantations requiring immunosuppression.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
研究衡量的是什么?
主要结果指标
结果测量 |
---|
To compare the efficacy of Rosiglitazone in combination with pegylated interferon alfa-2a and ribavirin (weight-based) to that of pegylated interferon alfa-2a and ribavirin alone in terms of sustained viral response.
|
次要结果测量
结果测量 |
---|
To compare the safety and tolerability of Rosiglitazone in combination with pegylated interferon-2a and ribavirin to that of pegylated interferon alfa-2a and ribavirin alone in terms of adverse events.
|
合作者和调查者
调查人员
- 首席研究员:Douglas Meyer, M.D.、Beth Israel Medical Center
- 研究主任:Henry C. Bodenheimer, M.D.、Beth Israel Medical Center
研究记录日期
研究主要日期
学习开始
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.